🩸 Fanconi Anemia
A rare inherited disorder affecting the body's ability to repair DNA — causing bone marrow failure, increased cancer risk, and physical anomalies.
Comprehensive, evidence-based information for patients, families, and healthcare providers.
What Is Fanconi Anemia?
A rare inherited DNA repair disorder with complex systemic effects
Fanconi anemia is a DNA repair disorder, not only a blood disease
FA is caused by mutations in genes that form the Fanconi anemia DNA repair pathway. When this pathway fails, damaged DNA cannot be repaired, leading to chromosomal instability. This causes: progressive bone marrow failure (aplastic anemia), dramatically increased cancer risk (especially AML and squamous cell carcinoma), and developmental physical anomalies in many patients.
Inheritance Pattern
Most FA subtypes are autosomal recessive — a child must inherit one mutated FANC gene from each parent. FANCB follows X-linked recessive inheritance (males predominantly affected). Carriers (one mutation) are unaffected but can pass the mutation to children.
Who Is Affected
FA affects all ethnicities but certain populations have higher carrier rates: Ashkenazi Jewish (FANCC IVS4+4A>T), Afrikaner South Africans (FANCA del exon 11-17), and Spanish Roma (FANCA exon 4). Median age of diagnosis: 7 years. Symptoms of bone marrow failure typically begin in childhood.
Physical Anomalies
Approximately 60-75% of patients have at least one physical anomaly: thumb/radial ray abnormalities (most common), skin café-au-lait spots, short stature, kidney malformations, hearing loss, microcephaly, eye abnormalities, or hypogonadism. About 25-40% have no physical anomalies.
Genetics of Fanconi Anemia
22+ FANC genes and the DNA repair pathway
| Gene | % of FA Cases | Notes |
|---|---|---|
| FANCA | ~60-65% | Most common; multiple ethnic-specific founder mutations |
| FANCC | ~10-15% | Common in Ashkenazi Jewish population |
| FANCG | ~10% | Often associated with more severe disease |
| FANCD2 | ~3-4% | Core pathway protein; more severe phenotype |
| BRCA2 (FANCD1) | ~2% | Associated with early-onset solid tumors (medulloblastoma, Wilms tumor) |
| FANCB | Very rare | X-linked; most severe form, often early lethal |
| All others | ~5-10% | FANCE, FANCF, FANCI, FANCJ, FANCL, FANCM, FANCN, FANCO, FANCP, FANCQ, FANCR, FANCS, FANCT, FANCU, FANCV, FANCW |
Diagnosis
Chromosome breakage testing is the gold standard
Chromosome Breakage Test
The gold standard diagnostic test: blood lymphocytes are exposed to crosslinking agents (DEB — diepoxybutane, or MMC — mitomycin C). FA cells show dramatically increased chromosomal breakage and radial figure formation. A positive DEB/MMC test is diagnostic. Skin fibroblasts can be used if blood mosaicism is suspected.
Genetic Testing
After positive chromosome breakage test, gene sequencing (multigene FA panel) identifies the specific gene mutation. This determines FA subtype (complementation group), guides cancer surveillance protocols, and is essential for donor selection in HSCT. Prenatal diagnosis is possible once the family mutation is known.
Somatic Mosaicism
~10-25% of FA patients have somatic mosaicism — spontaneous reversion of the mutation in some blood cells. These patients may have falsely normal DEB test from blood. If mosaicism is suspected, testing fibroblasts from skin biopsy is required. Mosaicism can be protective for bone marrow failure but does not protect against solid tumors.
Complications
Bone marrow failure, leukemia, and solid tumor risk
Bone Marrow Failure
Progressive pancytopenia (low red cells, white cells, platelets) is the most immediate life threat. Typical onset: first decade of life. Signs include fatigue, recurrent infections, easy bruising, petechiae. Regular CBC monitoring is essential from diagnosis.
Leukemia (AML/MDS)
FA patients have dramatically increased risk of acute myeloid leukemia and myelodysplastic syndrome. These often arise from the FA bone marrow failure clone. HSCT cures bone marrow failure and largely prevents AML/MDS — it is why timely transplant is critical.
Solid Tumors
Post-HSCT, FA patients face extremely high risk of squamous cell carcinoma (SCC) — particularly of the head, neck, esophagus, and anogenital region. Risk increases with age. HPV vaccination, alcohol and tobacco avoidance, and annual surveillance are essential. Radiation therapy dramatically increases SCC risk in FA patients.
Treatments
Hematopoietic stem cell transplant, androgens, and emerging gene therapy
HSCT (bone marrow transplant) is the only cure for bone marrow failure in FA
Hematopoietic stem cell transplant replaces the failing bone marrow with healthy donor stem cells. FA-specific reduced-intensity conditioning regimens are essential — standard high-dose conditioning used in other transplants is toxic to FA patients due to their DNA repair defect. Best outcomes: matched sibling donor, pre-bone marrow failure, young age.
HSCT — Bone Marrow Transplant
FA-specific conditioning protocols use fludarabine-based regimens at reduced doses. Matched sibling donor = best outcomes (~90% overall survival). Matched unrelated donor outcomes have improved significantly with modern protocols. Cord blood and haploidentical (half-matched) transplants are options when MSD is unavailable.
Androgen Therapy
Oxymetholone or other androgens temporarily improve blood counts in ~50-70% of patients, delaying the need for HSCT. They are not curative and have side effects (liver toxicity, virilization, stunted growth). Useful as a bridge to transplant or when transplant is not immediately possible.
Gene Therapy (Emerging)
Gene therapy for FANCA FA is in advanced clinical trials. The approach: correct the patient's own stem cells with a viral vector carrying a functional FANCA gene, then reinfuse — avoiding donor-matching issues and graft-versus-host disease. Phase I/II results (FANCOLEN-I trial, Barcelona) have shown promising safety and early efficacy.
Clinical Trials
Actively recruiting and recent completed trials
FANCOLEN-2 (Gene Therapy)
Phase II gene therapy trial for FANCA FA. Using lentiviral vector to correct autologous hematopoietic stem cells. Building on promising FANCOLEN-1 results. Search ClinicalTrials.gov
FANC Gene Therapy for Other Subtypes
Gene therapy trials are also in development for FANCC and FANCG subtypes. FARF (Fanconi Anemia Research Fund) coordinates international research. Registry participation helps advance research.
Transplant Protocol Studies
Ongoing studies improving HSCT outcomes in FA, particularly for mismatched donors and adult patients. Treosulfan-based conditioning is being studied as an alternative to busulfan/cyclophosphamide regimens.
Surveillance Protocol
Life-long monitoring is essential for all FA patients
| Screening | Frequency | Purpose |
|---|---|---|
| Complete Blood Count (CBC) | Every 3-6 months | Monitor for bone marrow failure progression |
| Bone Marrow Evaluation (biopsy + cytogenetics) | Annually or when CBC changes | Detect MDS/AML early |
| Head & Neck ENT examination | Annually (more frequent post-HSCT) | Early detection of SCC |
| Gynecological exam (females) | Annually from age 13 or sexual debut | Anogenital SCC surveillance |
| Endocrine assessment (thyroid, growth, hormones) | Annually | Detect endocrine complications |
| Audiology | As indicated | Hearing loss (especially post-HSCT with drug toxicity) |
| HPV vaccination | Per schedule (ideally before HSCT) | Reduce SCC risk |
Full guidelines: FARF Clinical Practice Guidelines
Mental Health & Family Support
Living with uncertainty: supporting patients and families
FA has profound psychological impact on the entire family
FA is diagnosed in childhood, involves life-threatening complications, requires intense medical surveillance, and may affect siblings (recurrence risk 25%). Parental guilt, anticipatory grief, and caregiver burnout are common. Siblings may feel neglected or survivor's guilt if unaffected. Early psychological support for the whole family improves outcomes.
Family-Centered Care
Best-practice FA centers provide psychosocial support as a standard part of care. This includes: genetic counseling for parents and adult siblings, psychological support during transplant, school re-integration planning after HSCT, and transitional care planning for adolescents moving to adult medicine.
Peer & Community Support
FARF provides family camps and peer connection programs. Connecting with other FA families reduces isolation and provides practical wisdom on navigating complex medical systems. Online communities offer real-time support globally.
International Resources
Patient organizations, specialist centers, and research networks
Fanconi Anemia Research Fund (FARF)
The leading international organization funding FA research and supporting families. Provides clinical practice guidelines, family camps, specialist center directory, and the FA scientific symposium. Based in the US but serves families worldwide.
fanconi.orgEuropean Reference Network — EuroBloodNet
EU network connecting rare blood disorder specialists across Europe. FA patients in Europe can access ERN expertise for diagnosis and treatment. The ERN GUARD-HEART also covers hereditary cardiac conditions associated with FA.
eurobloodnet.euComprehensive FA Centers
Specialized FA centers with full multidisciplinary expertise: Rockefeller University (NY), Cincinnati Children's, University of Minnesota, Hospital Vall d'Hebron (Barcelona), Hannover Medical School. These centers manage complex cases and conduct leading research.
FA Research Consortium
International research network coordinating FA science and clinical trials. Patient registries are maintained by FARF and the International Fanconi Anemia Registry (IFAR) at Rockefeller University — participation contributes to research.
FA Research ConsortiumMore CarePedia Portals
Evidence-based information portals for complex and rare conditions worldwide.
Browse All Portals →